Safety and immediate humoral response of COVID-19 vaccines in chronic kidney disease patients: the SENCOVAC study.
Borja QuirogaMaria José SolerAlberto Ortiz ArduanShaira Martínez VaqueraCarlos Jesús Jarava MantecónGustavo UsecheMaría Gabriela Sánchez MárquezManuel CarnereroMaría Teresa Jaldo RodríguezPatricia Muñoz RamosJuan Carlos Ruiz San MillánNestor G ToapantaCarolina Gracia-IguacelMaría Cinta Aguilar CerveraNoelia Balibrea LaraAlba LeyvaJosé RojasRon T GansevoortPatricia de SequeraPublished in: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2021)
The rate of anti-Spike antibody development after vaccination in KT patients was low but in other CKD patients it approached 100%; suggesting that KT patients require persistent isolation measures and booster doses of a Covid-19 vaccine. Potential differences between Covid-19 vaccines should be explored in prospective controlled studies.